The influence of gonadotropin releasing hormone agonist treatment on the body weight and body mass index in girls with idiopathic precocious puberty and early puberty
Sung-Woo KIM; Young-Bae KIM; Jeong-Eun LEE; Na-Ri KIM; Weon-Kyung LEE; Jae-Kyun KU; Eun-Jeong KIM; Sun-Hee JUNG; Woo-Yeong CHUNG.
Annals of Pediatric Endocrinology & Metabolism
; : 95-101, 2017.
Artículo
en Inglés
| WPRIM | ID: wpr-49254
PURPOSE:
This study aimed to investigate the influence of gonadotropin releasing hormone agonist (GnRHa) treatment on the weight and body mass index (BMI) of girls who were diagnosed with idiopathic central precocious puberty (CPP) or early puberty (EP).METHODS:
Patients who were younger than 8 years of age at diagnosis were classified as CPP and patients aged between 8 and 9 years at diagnosis were classified as EP. Of 129 patients, 34 were diagnosed with CPP and 95 were diagnosed with EP. The patients were divided according to pretreatment weight status into normal weight group, an overweight group, or an obese group.RESULTS:
No significant changes were observed with respect to the weight standard deviation score (SDS) before and after 1 year, 2 years of treatment, respectively (P>0.05, P>0.05) in all patient groups. No significant changes were observed in relation to the BMI SDS before and after 1 year, 2 years of treatment, respectively (P>0.05, P>0.05) in all patient group. Depending on the degree of obesity, differences with respect to the weight SDS and BMI SDS were observed.CONCLUSION:
BMI SDS increased in the GnRHa-treated patients as a whole group, but was not statistically significant. But BMI SDS increased significantly in the normal weight group after 2 years of GnRHa treatment. So, GnRHa treatment may affect the change of BMI SDS depending on degree of obesity.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados